Clinical Trial Update: Safety and Immunogenicity of the RSV D46cpΔM2-2 Vaccine in RSV-Seropositive Children and RSV-Seronegative Infants and Children [Phase 1]

View source ↗

Summary

Phase 1 trial results evaluating the safety and immunogenicity of the RSV D46cpΔM2-2 vaccine in RSV-seropositive children and RSV-seronegative infants/children;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infections

Drugs mentioned

• RSV D46cpΔM2-2 vaccine

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Respiratory Syncytial Virus Infections | Phase 1 | Status: COMPLETED